<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 13 Jun 2024 10:09:36 +0000</lastbuilddate>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>RNA and the emerging potential of bio-inspired molecules in cardiovascular disease therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866524/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 13:ehae348. doi: 10.1093/eurheartj/ehae348. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866524/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866524</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae348>10.1093/eurheartj/ehae348</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866524</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Noreen Ahmed</dc:creator>
<dc:creator>Darryl R Davis</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>RNA and the emerging potential of bio-inspired molecules in cardiovascular disease therapies</dc:title>
<dc:identifier>pmid:38866524</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae348</dc:identifier>
</item>
<item>
<title>Sex-related differences in degenerative mitral regurgitation: a call to action</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866496/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 13:ehae360. doi: 10.1093/eurheartj/ehae360. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866496/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866496</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae360>10.1093/eurheartj/ehae360</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866496</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sex-related differences in degenerative mitral regurgitation: a call to action</dc:title>
<dc:identifier>pmid:38866496</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae360</dc:identifier>
</item>
<item>
<title>Reply: Use of Percutaneous Therapies as a Bridge to Surgery in Patients With Right-Sided Infective Endocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866453/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):e241. doi: 10.1016/j.jacc.2024.04.019.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866453/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866453</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.019>10.1016/j.jacc.2024.04.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866453</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Haytham Elgharably</dc:creator>
<dc:creator>Steven Gordon</dc:creator>
<dc:creator>Joanna Ghobrial</dc:creator>
<dc:creator>Gösta B Pettersson</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Use of Percutaneous Therapies as a Bridge to Surgery in Patients With Right-Sided Infective Endocarditis</dc:title>
<dc:identifier>pmid:38866453</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.019</dc:identifier>
</item>
<item>
<title>Use of Percutaneous Therapies as a Bridge to Surgery in Patients With Right-Sided Infective Endocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866452/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):e239. doi: 10.1016/j.jacc.2024.03.428.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866452/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866452</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.428>10.1016/j.jacc.2024.03.428</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866452</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>V Seenu Reddy</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Use of Percutaneous Therapies as a Bridge to Surgery in Patients With Right-Sided Infective Endocarditis</dc:title>
<dc:identifier>pmid:38866452</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.428</dc:identifier>
</item>
<item>
<title>Turning Data Into Action: The JACC Global Burden of Cardiovascular Diseases and Risks Interactive Tool and Resources</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866451/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):2610-2613. doi: 10.1016/j.jacc.2024.05.007.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866451/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866451</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.007>10.1016/j.jacc.2024.05.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866451</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>George A Mensah</dc:creator>
<dc:creator>Taryn Myers</dc:creator>
<dc:creator>Ron Schmelzer</dc:creator>
<dc:creator>Shlomo Spaeth</dc:creator>
<dc:creator>Gregory A Roth</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Turning Data Into Action: The JACC Global Burden of Cardiovascular Diseases and Risks Interactive Tool and Resources</dc:title>
<dc:identifier>pmid:38866451</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.007</dc:identifier>
</item>
<item>
<title>Gender Diversity in Cardiovascular Journal Authorship: So Much Time, So Little Progress</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866450/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):2469-2471. doi: 10.1016/j.jacc.2024.04.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866450/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866450</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.020>10.1016/j.jacc.2024.04.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866450</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Mary Norine Walsh</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Gender Diversity in Cardiovascular Journal Authorship: So Much Time, So Little Progress</dc:title>
<dc:identifier>pmid:38866450</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.020</dc:identifier>
</item>
<item>
<title>Geographic Mapping of Gender Disparities in Authorship of Cardiovascular Literature</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866449/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Over the past decade, the proportion of women authors across all article types in major cardiovascular journals remained low. A call to action is needed to promote women in cardiology and provide them with equitable opportunities.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):2458-2468. doi: 10.1016/j.jacc.2024.03.427.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Women in cardiology experience considerable gender disparities in publications, which hinders their career advancements to higher faculty and senior leadership positions. However, the extent of these disparities across different types of cardiovascular literature is not well understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We investigated gender differences in authorship across various cardiovascular publications over a decade and examined geographic variations in the representation of women authors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All papers published from January 1, 2010, to December 31, 2019, in 4 major cardiovascular journals (Journal of the American College of Cardiology, European Heart Journal, Journal of the American Medical Association Cardiology, and Nature Reviews Cardiology) were reviewed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 18,535 papers with 111,562 authors, 20.6% of the authors were women, and 47.7% of the papers had no women authors. Over 10 years, the proportion of women authors remained low (20.7% in 2010 to 21.4% in 2019), with the lowest proportion in editorial papers (14.8%) and the highest in research papers (21.8%). More women as first (34.6%) and last (47.6%) authors were affiliated with institutions in the United States compared with other countries. The proportion of women middle-order authors was higher on papers with women as first authors (29.4% vs 20.5%) or last authors (30.6% vs 21.3%), compared with papers with men as first or last authors, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Over the past decade, the proportion of women authors across all article types in major cardiovascular journals remained low. A call to action is needed to promote women in cardiology and provide them with equitable opportunities.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866449/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866449</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.427>10.1016/j.jacc.2024.03.427</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866449</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ridhima Goel</dc:creator>
<dc:creator>Samantha Sartori</dc:creator>
<dc:creator>Birgit Vogel</dc:creator>
<dc:creator>Kimberly Okoli</dc:creator>
<dc:creator>Kayla Franklin-Bedel</dc:creator>
<dc:creator>Rebecca Ortega</dc:creator>
<dc:creator>Dee Dee Wang</dc:creator>
<dc:creator>Pamela S Douglas</dc:creator>
<dc:creator>Tracy Y Wang</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Women As One Scientific Expert Panel</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Geographic Mapping of Gender Disparities in Authorship of Cardiovascular Literature</dc:title>
<dc:identifier>pmid:38866449</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.427</dc:identifier>
</item>
<item>
<title>Equitable Health Care for Children: The Next Horizon of Change</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866448/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):2455-2457. doi: 10.1016/j.jacc.2024.04.032.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866448/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866448</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.032>10.1016/j.jacc.2024.04.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866448</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Meena Nathan</dc:creator>
<dc:creator>Emily Bucholz</dc:creator>
<dc:creator>Katie M Moynihan</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Equitable Health Care for Children: The Next Horizon of Change</dc:title>
<dc:identifier>pmid:38866448</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.032</dc:identifier>
</item>
<item>
<title>Impact of Social Determinants of Health on Predictive Models for Outcomes After Congenital Heart Surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866447/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Although indiscriminate inclusion of social determinants in clinical risk modeling can conceal inequities, thoughtful consideration can help centers understand their performance across populations and guide efforts to improve health equity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):2440-2454. doi: 10.1016/j.jacc.2024.03.430.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite documented associations between social determinants of health and outcomes post-congenital heart surgery, clinical risk models typically exclude these factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The study sought to characterize associations between social determinants and operative and longitudinal mortality as well as assess impacts on risk model performance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Demographic and clinical data were obtained for all congenital heart surgeries (2006-2021) from locally held Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources Society of Thoracic Surgeons Congenital Heart Surgery Database data. Neighborhood-level American Community Survey and composite sociodemographic measures were linked by zip code. Model prediction, discrimination, and impact on quality assessment were assessed before and after inclusion of social determinants in models based on the 2020 Society of Thoracic Surgeons Congenital Heart Surgery Database Mortality Risk Model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 14,173 total index operations across New York State, 12,321 cases, representing 10,271 patients at 8 centers, had zip codes for linkage. A total of 327 (2.7%) patients died in the hospital or before 30 days, and 314 children died by December 31, 2021 (total n = 641; 6.2%). Multiple measures of social determinants of health explained as much or more variability in operative and longitudinal mortality than clinical comorbidities or prior cardiac surgery. Inclusion of social determinants minimally improved models' predictive performance (operative: 0.834-0.844; longitudinal 0.808-0.811), but significantly improved model discrimination; 10.0% more survivors and 4.8% more mortalities were appropriately risk classified with inclusion. Wide variation in reclassification was observed by site, resulting in changes in the center performance classification category for 2 of 8 centers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Although indiscriminate inclusion of social determinants in clinical risk modeling can conceal inequities, thoughtful consideration can help centers understand their performance across populations and guide efforts to improve health equity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866447/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866447</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.430>10.1016/j.jacc.2024.03.430</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866447</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarah Crook</dc:creator>
<dc:creator>Kacie Dragan</dc:creator>
<dc:creator>Joyce L Woo</dc:creator>
<dc:creator>Matthew Neidell</dc:creator>
<dc:creator>Katherine A Nash</dc:creator>
<dc:creator>Pengfei Jiang</dc:creator>
<dc:creator>Yun Zhang</dc:creator>
<dc:creator>Chantal M Sanchez</dc:creator>
<dc:creator>Stephen Cook</dc:creator>
<dc:creator>Edward L Hannan</dc:creator>
<dc:creator>Jane W Newburger</dc:creator>
<dc:creator>Marshall L Jacobs</dc:creator>
<dc:creator>Christopher J Petit</dc:creator>
<dc:creator>Andrew Goldstone</dc:creator>
<dc:creator>Robert Vincent</dc:creator>
<dc:creator>Kathleen Walsh-Spoonhower</dc:creator>
<dc:creator>Ralph Mosca</dc:creator>
<dc:creator>T K Susheel Kumar</dc:creator>
<dc:creator>Neil Devejian</dc:creator>
<dc:creator>Ben Biddix</dc:creator>
<dc:creator>George M Alfieris</dc:creator>
<dc:creator>Michael F Swartz</dc:creator>
<dc:creator>David Meyer</dc:creator>
<dc:creator>Erin A Paul</dc:creator>
<dc:creator>John Billings</dc:creator>
<dc:creator>Brett R Anderson</dc:creator>
<dc:creator>New York State Congenital Heart Surgery Collaborative for Longitudinal Outcomes &amp; Utilization of Resources (CHS-COLOUR)</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Social Determinants of Health on Predictive Models for Outcomes After Congenital Heart Surgery</dc:title>
<dc:identifier>pmid:38866447</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.430</dc:identifier>
</item>
<item>
<title>As Good as it Gets: SGLT2 Inhibitors in Cardiac Amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866446/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):2423-2425. doi: 10.1016/j.jacc.2024.04.024.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866446/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866446</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.024>10.1016/j.jacc.2024.04.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866446</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Sean P Pinney</dc:creator>
<dc:creator>Maria Rosa Costanzo</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>As Good as it Gets: SGLT2 Inhibitors in Cardiac Amyloidosis</dc:title>
<dc:identifier>pmid:38866446</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.024</dc:identifier>
</item>
<item>
<title>SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866445/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: SGLT2i treatment in ATTR-CM patients was well tolerated and associated with favorable effects on HF symptoms, renal function, and diuretic agent requirement over time. SGLT2i treatment was associated with reduced risk of HF hospitalization and cardiovascular and all-cause mortality, regardless of the ejection fraction, despite the effect size being likely overestimated. In the absence of randomized trials, these data may inform clinicians regarding the use of SGLT2i in patients with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 18;83(24):2411-2422. doi: 10.1016/j.jacc.2024.03.429.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Transthyretin cardiomyopathy (ATTR-CM) was an exclusion criterion in randomized clinical trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to assess the effectiveness and tolerability of SGLT2i in patients with ATTR-CM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data of 2,356 consecutive ATTR-CM patients (2014-2022) were analyzed: 260 (11%) received SGLT2i. After comparing the groups according to the treatment, 14 variables were significantly different-age and N-terminal pro-B-type natriuretic peptide were included in the model. A propensity score reflecting the likelihood of being treated with SGLT2i for each patient was determined using 16 variables.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study comprised 220 patients treated with SGLT2i (age 77 ± 2 years; 82.3% wild-type ATTR-CM; left ventricular ejection fraction 45.8% ± 11%) and 220 propensity-matched control individuals. Adequacy of matching was verified (standardized differences: &lt;0.10 between groups). Discontinuation rate for SGLT2i was 4.5%; at 12 months, SGLT2i treatment was associated with less worsening of NYHA functional class, N-terminal pro-B-type natriuretic peptide, estimated glomerular filtration rate, and fewer new initiations of loop diuretic agent therapy. Over 28 months (Q1-Q3: 18-45 months), SGLT2i therapy was associated with lower all-cause mortality (HR: 0.57; 95% CI: 0.37-0.89; P = 0.010), cardiovascular mortality (HR: 0.41; 95% CI: 0.24-0.71; P &lt; 0.001), heart failure (HF) hospitalization (HR: 0.57; 95% CI: 0.36-0.91; P = 0.014), and the composite outcome of cardiovascular mortality and HF hospitalization (HR: 0.57; 95% CI: 0.38-0.84; P = 0.003).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SGLT2i treatment in ATTR-CM patients was well tolerated and associated with favorable effects on HF symptoms, renal function, and diuretic agent requirement over time. SGLT2i treatment was associated with reduced risk of HF hospitalization and cardiovascular and all-cause mortality, regardless of the ejection fraction, despite the effect size being likely overestimated. In the absence of randomized trials, these data may inform clinicians regarding the use of SGLT2i in patients with ATTR-CM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866445/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866445</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.429>10.1016/j.jacc.2024.03.429</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866445</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Aldostefano Porcari</dc:creator>
<dc:creator>Francesco Cappelli</dc:creator>
<dc:creator>Christian Nitsche</dc:creator>
<dc:creator>Daniela Tomasoni</dc:creator>
<dc:creator>Giulio Sinigiani</dc:creator>
<dc:creator>Simone Longhi</dc:creator>
<dc:creator>Luca Bordignon</dc:creator>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Matteo Serenelli</dc:creator>
<dc:creator>Marcus Urey</dc:creator>
<dc:creator>Beatrice Musumeci</dc:creator>
<dc:creator>Alberto Cipriani</dc:creator>
<dc:creator>Marco Canepa</dc:creator>
<dc:creator>Roza Badr-Eslam</dc:creator>
<dc:creator>Christina Kronberger</dc:creator>
<dc:creator>Cristina Chimenti</dc:creator>
<dc:creator>Mattia Zampieri</dc:creator>
<dc:creator>Valentina Allegro</dc:creator>
<dc:creator>Yousuf Razvi</dc:creator>
<dc:creator>Rishi Patel</dc:creator>
<dc:creator>Adam Ioannou</dc:creator>
<dc:creator>Muhammad U Rauf</dc:creator>
<dc:creator>Aviva Petrie</dc:creator>
<dc:creator>Carol Whelan</dc:creator>
<dc:creator>Michele Emdin</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Philip N Hawkins</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy</dc:title>
<dc:identifier>pmid:38866445</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.429</dc:identifier>
</item>
<item>
<title>Single-molecule imaging reveals the mechanism of bidirectional replication initiation in metazoa</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866019/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>Metazoan genomes are copied bidirectionally from thousands of replication origins. Replication initiation entails the assembly and activation of two CMG helicases (Cdc45⋅Mcm2-7⋅GINS) at each origin. This requires several replication firing factors (including TopBP1, RecQL4, and DONSON) whose exact roles are still under debate. How two helicases are correctly assembled and activated at each origin is a long-standing question. By visualizing the recruitment of GINS, Cdc45, TopBP1, RecQL4, and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 7:S0092-8674(24)00533-6. doi: 10.1016/j.cell.2024.05.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Metazoan genomes are copied bidirectionally from thousands of replication origins. Replication initiation entails the assembly and activation of two CMG helicases (Cdc45⋅Mcm2-7⋅GINS) at each origin. This requires several replication firing factors (including TopBP1, RecQL4, and DONSON) whose exact roles are still under debate. How two helicases are correctly assembled and activated at each origin is a long-standing question. By visualizing the recruitment of GINS, Cdc45, TopBP1, RecQL4, and DONSON in real time, we uncovered that replication initiation is surprisingly dynamic. First, TopBP1 transiently binds to the origin and dissociates before the start of DNA synthesis. Second, two Cdc45 are recruited together, even though Cdc45 alone cannot dimerize. Next, two copies of DONSON and two GINS simultaneously arrive at the origin, completing the assembly of two CMG helicases. Finally, RecQL4 is recruited to the CMG⋅DONSON⋅DONSON⋅CMG complex and promotes DONSON dissociation and CMG activation via its ATPase activity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866019/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866019</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.024>10.1016/j.cell.2024.05.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866019</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Riki Terui</dc:creator>
<dc:creator>Scott E Berger</dc:creator>
<dc:creator>Larissa A Sambel</dc:creator>
<dc:creator>Dan Song</dc:creator>
<dc:creator>Gheorghe Chistol</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Single-molecule imaging reveals the mechanism of bidirectional replication initiation in metazoa</dc:title>
<dc:identifier>pmid:38866019</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.024</dc:identifier>
</item>
<item>
<title>Minimal and hybrid hydrogenases are active from archaea</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866018/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>Microbial hydrogen (H(2)) cycling underpins the diversity and functionality of diverse anoxic ecosystems. Among the three evolutionarily distinct hydrogenase superfamilies responsible, [FeFe] hydrogenases were thought to be restricted to bacteria and eukaryotes. Here, we show that anaerobic archaea encode diverse, active, and ancient lineages of [FeFe] hydrogenases through combining analysis of existing and new genomes with extensive biochemical experiments. [FeFe] hydrogenases are encoded by...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 7:S0092-8674(24)00573-7. doi: 10.1016/j.cell.2024.05.032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Microbial hydrogen (H<sub>2</sub>) cycling underpins the diversity and functionality of diverse anoxic ecosystems. Among the three evolutionarily distinct hydrogenase superfamilies responsible, [FeFe] hydrogenases were thought to be restricted to bacteria and eukaryotes. Here, we show that anaerobic archaea encode diverse, active, and ancient lineages of [FeFe] hydrogenases through combining analysis of existing and new genomes with extensive biochemical experiments. [FeFe] hydrogenases are encoded by genomes of nine archaeal phyla and expressed by H<sub>2</sub>-producing Asgard archaeon cultures. We report an ultraminimal hydrogenase in DPANN archaea that binds the catalytic H-cluster and produces H<sub>2</sub>. Moreover, we identify and characterize remarkable hybrid complexes formed through the fusion of [FeFe] and [NiFe] hydrogenases in ten other archaeal orders. Phylogenetic analysis and structural modeling suggest a deep evolutionary history of hybrid hydrogenases. These findings reveal new metabolic adaptations of archaea, streamlined H<sub>2</sub> catalysts for biotechnological development, and a surprisingly intertwined evolutionary history between the two major H<sub>2</sub>-metabolizing enzymes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866018/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866018</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.032>10.1016/j.cell.2024.05.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866018</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Chris Greening</dc:creator>
<dc:creator>Princess R Cabotaje</dc:creator>
<dc:creator>Luis E Valentin Alvarado</dc:creator>
<dc:creator>Pok Man Leung</dc:creator>
<dc:creator>Henrik Land</dc:creator>
<dc:creator>Thiago Rodrigues-Oliveira</dc:creator>
<dc:creator>Rafael I Ponce-Toledo</dc:creator>
<dc:creator>Moritz Senger</dc:creator>
<dc:creator>Max A Klamke</dc:creator>
<dc:creator>Michael Milton</dc:creator>
<dc:creator>Rachael Lappan</dc:creator>
<dc:creator>Susan Mullen</dc:creator>
<dc:creator>Jacob West-Roberts</dc:creator>
<dc:creator>Jie Mao</dc:creator>
<dc:creator>Jiangning Song</dc:creator>
<dc:creator>Marie Schoelmerich</dc:creator>
<dc:creator>Courtney W Stairs</dc:creator>
<dc:creator>Christa Schleper</dc:creator>
<dc:creator>Rhys Grinter</dc:creator>
<dc:creator>Anja Spang</dc:creator>
<dc:creator>Jillian F Banfield</dc:creator>
<dc:creator>Gustav Berggren</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Minimal and hybrid hydrogenases are active from archaea</dc:title>
<dc:identifier>pmid:38866018</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.032</dc:identifier>
</item>
<item>
<title>TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866017/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>Ongoing, early-stage clinical trials illustrate the translational potential of human pluripotent stem cell (hPSC)-based cell therapies in Parkinson's disease (PD). However, an unresolved challenge is the extensive cell death following transplantation. Here, we performed a pooled CRISPR-Cas9 screen to enhance postmitotic dopamine neuron survival in vivo. We identified p53-mediated apoptotic cell death as a major contributor to dopamine neuron loss and uncovered a causal link of tumor necrosis...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 5:S0092-8674(24)00575-0. doi: 10.1016/j.cell.2024.05.030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ongoing, early-stage clinical trials illustrate the translational potential of human pluripotent stem cell (hPSC)-based cell therapies in Parkinson's disease (PD). However, an unresolved challenge is the extensive cell death following transplantation. Here, we performed a pooled CRISPR-Cas9 screen to enhance postmitotic dopamine neuron survival in vivo. We identified p53-mediated apoptotic cell death as a major contributor to dopamine neuron loss and uncovered a causal link of tumor necrosis factor alpha (TNF-α)-nuclear factor κB (NF-κB) signaling in limiting cell survival. As a translationally relevant strategy to purify postmitotic dopamine neurons, we identified cell surface markers that enable purification without the need for genetic reporters. Combining cell sorting and treatment with adalimumab, a clinically approved TNF-α inhibitor, enabled efficient engraftment of postmitotic dopamine neurons with extensive reinnervation and functional recovery in a preclinical PD mouse model. Thus, transient TNF-α inhibition presents a clinically relevant strategy to enhance survival and enable engraftment of postmitotic hPSC-derived dopamine neurons in PD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866017/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866017</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.030>10.1016/j.cell.2024.05.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866017</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Tae Wan Kim</dc:creator>
<dc:creator>So Yeon Koo</dc:creator>
<dc:creator>Markus Riessland</dc:creator>
<dc:creator>Fayzan Chaudhry</dc:creator>
<dc:creator>Benjamin Kolisnyk</dc:creator>
<dc:creator>Hyein S Cho</dc:creator>
<dc:creator>Marco Vincenzo Russo</dc:creator>
<dc:creator>Nathalie Saurat</dc:creator>
<dc:creator>Sanjoy Mehta</dc:creator>
<dc:creator>Ralph Garippa</dc:creator>
<dc:creator>Doron Betel</dc:creator>
<dc:creator>Lorenz Studer</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons</dc:title>
<dc:identifier>pmid:38866017</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.030</dc:identifier>
</item>
<item>
<title>Epigenetic changes in HSCs contribute to HF and comorbidities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38866904/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 12. doi: 10.1038/s41569-024-01051-9. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38866904/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38866904</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01051-9>10.1038/s41569-024-01051-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38866904</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Epigenetic changes in HSCs contribute to HF and comorbidities</dc:title>
<dc:identifier>pmid:38866904</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01051-9</dc:identifier>
</item>
<item>
<title>Simultaneous transcatheter aortic and tricuspid valve replacement via bilateral cervical approach</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865357/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 12:ehae352. doi: 10.1093/eurheartj/ehae352. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865357/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38865357</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae352>10.1093/eurheartj/ehae352</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865357</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Yu Zhuang</dc:creator>
<dc:creator>Wei Wang</dc:creator>
<dc:creator>Fanglin Lu</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Simultaneous transcatheter aortic and tricuspid valve replacement via bilateral cervical approach</dc:title>
<dc:identifier>pmid:38865357</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae352</dc:identifier>
</item>
<item>
<title>Interventional occlusion treatment of pulmonary artery-aortic aneurysm residual cavity fistula after aortic repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865347/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 12:ehae370. doi: 10.1093/eurheartj/ehae370. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865347/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38865347</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae370>10.1093/eurheartj/ehae370</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865347</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Zihao Li</dc:creator>
<dc:creator>Hongwei Zhang</dc:creator>
<dc:creator>Simin Lin</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Interventional occlusion treatment of pulmonary artery-aortic aneurysm residual cavity fistula after aortic repair</dc:title>
<dc:identifier>pmid:38865347</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae370</dc:identifier>
</item>
<item>
<title>Perforation of the right ventricle and pulmonary artery embolism by bone cement after percutaneous vertebroplasty</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865341/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 12:ehae369. doi: 10.1093/eurheartj/ehae369. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865341/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38865341</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae369>10.1093/eurheartj/ehae369</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865341</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Shi-Xiong Wu</dc:creator>
<dc:creator>Chen Huang</dc:creator>
<dc:creator>Jing Xu</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Perforation of the right ventricle and pulmonary artery embolism by bone cement after percutaneous vertebroplasty</dc:title>
<dc:identifier>pmid:38865341</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae369</dc:identifier>
</item>
<item>
<title>Non-coding RNA yREX3 from human extracellular vesicles exerts macrophage-mediated cardioprotection via a novel gene-methylating mechanism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865332/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings highlight the role of a small Y RNA mined from EVs with a novel gene-methylating mechanism.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 12:ehae357. doi: 10.1093/eurheartj/ehae357. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Extracellular vesicles (EVs) secreted by cardiosphere-derived cells exert immunomodulatory effects through the transmission of small non-coding RNAs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The mechanism and role of yREX3, a small Y RNA abundant in EVs in myocardial injury, was investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: yREX3 attenuates cardiac ischaemic injury by selective DNA methylation. Synthetic yREX3 encapsulated in lipid nanoparticles triggers broad transcriptomic changes in macrophages, localizes to the nucleus, and mediates epigenetic silencing of protein interacting with C kinase-1 (Pick1) through methylation of upstream CpG sites. Moreover, yREX3 interacts with polypyrimidine tract binding protein 3 (PTBP3) to methylate the Pick1 gene locus in a DNA methyltransferase-dependent manner. Suppression of Pick1 in macrophages potentiates Smad3 signalling and enhances efferocytosis, minimizing heart necrosis in rats with myocardial infarction. Adoptive transfer of Pick1-deficient macrophages recapitulates the cardioprotective effects of yREX3 in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings highlight the role of a small Y RNA mined from EVs with a novel gene-methylating mechanism.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865332/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38865332</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae357>10.1093/eurheartj/ehae357</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865332</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Alessandra Ciullo</dc:creator>
<dc:creator>Liang Li</dc:creator>
<dc:creator>Chang Li</dc:creator>
<dc:creator>Kara Tsi</dc:creator>
<dc:creator>Colin Farrell</dc:creator>
<dc:creator>Matteo Pellegrini</dc:creator>
<dc:creator>Eduardo Marbán</dc:creator>
<dc:creator>Ahmed G E Ibrahim</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Non-coding RNA yREX3 from human extracellular vesicles exerts macrophage-mediated cardioprotection via a novel gene-methylating mechanism</dc:title>
<dc:identifier>pmid:38865332</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae357</dc:identifier>
</item>
<item>
<title>Inflammation in cardio-oncology: beyond immunotherapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865293/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 12:ehae333. doi: 10.1093/eurheartj/ehae333. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865293/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38865293</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae333>10.1093/eurheartj/ehae333</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865293</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Anne Lise Ferrara</dc:creator>
<dc:creator>Stefania Loffredo</dc:creator>
<dc:creator>Carlo Gabriele Tocchetti</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inflammation in cardio-oncology: beyond immunotherapies</dc:title>
<dc:identifier>pmid:38865293</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae333</dc:identifier>
</item>
<item>
<title>Reflections of an Editorial Fellow-A Window Into Medical Publishing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865144/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240613060934&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jun 12. doi: 10.1001/jamacardio.2024.1330. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865144/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240613060934&v=2.18.0.post9+e462414">38865144</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1330>10.1001/jamacardio.2024.1330</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865144</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Vinay Guduguntla</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Reflections of an Editorial Fellow-A Window Into Medical Publishing</dc:title>
<dc:identifier>pmid:38865144</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1330</dc:identifier>
</item>





























</channel>
</rss>